Literature DB >> 10724022

Comparison of pivmecillinam and cephalexin in acute uncomplicated urinary tract infection.

A P Menday1.   

Abstract

The clinical and bacteriological efficacy of a 3-day course of pivmecillinam, 200 mg three times daily, was compared with that of a 7-day course of cephalexin, 250 mg four times daily, in 216 patients with a bacteriologically confirmed, acute, uncomplicated, urinary tract infection. Both treatments were similarly effective. Clinical cure or improvement was obtained in 95.3% of patients given pivmecillinam and in 93.6% of patients given cephalexin. Bacteriological success was achieved in 89.7 and 81.7% patients taking pivmecillinam or cephalexin, respectively. Eradication rates for Escherichia coli were 90.1% for pivmecillinam and 80.6% for cephalexin. Both treatments were well tolerated. This study has confirmed that a 3-day course of pivmecillinam is effective and well tolerated in uncomplicated cystitis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10724022     DOI: 10.1016/s0924-8579(99)00118-1

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  3 in total

1.  A Canadian national surveillance study of urinary tract isolates from outpatients: comparison of the activities of trimethoprim-sulfamethoxazole, ampicillin, mecillinam, nitrofurantoin, and ciprofloxacin. The Canadian Urinary Isolate Study Group.

Authors:  G G Zhanel; J A Karlowsky; G K Harding; A Carrie; T Mazzulli; D E Low; D J Hoban
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

Review 2.  Urinary tract infections in adult general practice patients.

Authors:  Eva Hummers-Pradier; Michael M Kochen
Journal:  Br J Gen Pract       Date:  2002-09       Impact factor: 5.386

3.  High rate of per oral mecillinam treatment failure in community-acquired urinary tract infections caused by ESBL-producing Escherichia coli.

Authors:  Arne Søraas; Arnfinn Sundsfjord; Silje Bakken Jørgensen; Knut Liestøl; Pål A Jenum
Journal:  PLoS One       Date:  2014-01-15       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.